Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment

被引:82
作者
Barber, Amorette [1 ]
Rynda, Agnieszka [1 ]
Sentman, Charles L. [1 ]
机构
[1] Dartmouth Med Sch, Dept Microbiol & Immunol, Lebanon, NH 03756 USA
基金
美国国家卫生研究院;
关键词
TOLL-LIKE RECEPTORS; INTERFERON-GAMMA; CANCER-IMMUNOTHERAPY; VASCULAR LEUKOCYTES; ACUTE TOXOPLASMOSIS; ANTITUMOR IMMUNITY; PROGNOSTIC-FACTORS; SUPPRESSOR-CELLS; NITRIC-OXIDE; PHASE-I/II;
D O I
10.4049/jimmunol.0902000
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Adoptive transfer of T cells expressing chimeric NKG2D (chNKG2D) receptors, a fusion of NKG2D and CD3 zeta, can lead to long-term, tumor-free survival in a murine model of ovarian cancer. To determine the mechanisms of chNKG2D T cell antitumor efficacy, we analyzed how chNKG2D T cells altered the tumor microenvironment, including the tumor-infiltrating leukocyte populations. chNKG2D T cell treatment of mice bearing ID8 tumor cells increased the number and activation of NK cells and increased the activation of host CD8(+) T cells within the tumor. Foxp3(+) regulatory T cells at the tumor site decreased more than 300-fold after chNKG2D T cell treatment. Tumor-associated regulatory T cells expressed cell surface NKG2D ligands and were killed by chNKG2D T cells in a perforin-dependent manner. chNKG2D T cells also altered the function of myeloid cells at the tumor site, changing these cells from being immunosuppressive to enhancing T cell responses. Cells isolated from the tumor produced elevated amounts of IFN-gamma, NO, and other proinflammatory cytokines after chNKG2D T cell treatment. ChNKG2D T cells required perforin, IFN-gamma, and GM-CSF to induce a full response at the tumor site. In addition, transfer of chNKG2D T cells into mice bearing tumors that were established for 5 weeks led to long-term survival of the mice. Thus, chNKG2D T cells altered the ovarian tumor microenvironment to eliminate immunosuppressive cells and induce infiltration and activation of antitumor immune cells and production of inflammatory cytokines. This induction of an immune response likely contributes to chNKG2D T cells' ability to eliminate established tumors. The Journal of Immunology, 2009, 183: 6939-6947.
引用
收藏
页码:6939 / 6947
页数:9
相关论文
共 46 条
[1]
Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression [J].
Bak, S. Peter ;
Alonso, Anselmo ;
Turk, Mary Jo ;
Berwin, Brent .
MOLECULAR IMMUNOLOGY, 2008, 46 (02) :258-268
[2]
Interleukin-10 modulates the sensitivity of peritoneal B lymphocytes to chemokines with opposite effects on stromal cell-derived factor-1 and B-lymphocyte chemoattractant [J].
Balabanian, K ;
Foussat, A ;
Bouchet-Delbos, L ;
Couderc, J ;
Krzysiek, R ;
Amara, A ;
Baleux, F ;
Portier, A ;
Galanaud, P ;
Emilie, D .
BLOOD, 2002, 99 (02) :427-436
[3]
Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer [J].
Barber, Amorette ;
Zhang, Tong ;
Sentman, Charles L. .
JOURNAL OF IMMUNOLOGY, 2008, 180 (01) :72-78
[4]
Chimeric NKG2D T Cells Require Both T Cell- and Host-Derived Cytokine Secretion and Perforin Expression to Increase Tumor Antigen Presentation and Systemic Immunity [J].
Barber, Amorette ;
Sentman, Charles L. .
JOURNAL OF IMMUNOLOGY, 2009, 183 (04) :2365-2372
[5]
Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer [J].
Barber, Arnorette ;
Zhang, Tong ;
DeMars, Leslie R. ;
Conejo-Garcia, Jose ;
Roby, Katherine F. ;
Sentman, Charles L. .
CANCER RESEARCH, 2007, 67 (10) :5003-5008
[6]
Regulatory T cells in ovarian cancer: Biology and therapeutic potential [J].
Barnett, B ;
Kryczek, I ;
Cheng, P ;
Zou, WP ;
Curiel, TJ .
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2005, 54 (06) :369-377
[7]
Barnett BG, 2008, ADV EXP MED BIOL, V622, P255, DOI 10.1007/978-0-387-68969-2_20
[8]
Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer [J].
Baur, M ;
Schernhammer, E ;
Gneist, M ;
Sevelda, P ;
Speiser, P ;
Hudec, M ;
Dittrich, C .
BRITISH JOURNAL OF CANCER, 2005, 92 (06) :1019-1025
[9]
The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis [J].
Blankenstein, T ;
Qin, ZH .
CURRENT OPINION IN IMMUNOLOGY, 2003, 15 (02) :148-154
[10]
Regulatory B cells as inhibitors of immune responses and inflammation [J].
Bouaziz, Jean-David ;
Yanaba, Koichi ;
Tedder, Thomas F. .
IMMUNOLOGICAL REVIEWS, 2008, 224 :201-214